COVID-19 - October 14, 2021
Are currently available T-cell tests reliable?
Funded by the National SciLifeLab-KAW COVID-19 Research Program, SciLifeLab researchers from Uppsala University, KTH and Karolinska Institutet have, under the umbrella of the COMMUNITY study, investigated if existing T-cell tests can be used to accurately determine if people have previously been infected with SARS-CoV-2. “We’ve seen that companies sell tests for the purpose of measuring […]
COVID-19 - October 12, 2021
AstraZeneca announces positive results from the TACKLE trial
New results from the TACKLE Phase III COVID-19 treatment trial showed that AZD7442, a long acting antibody (LAAB) combination, achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalized patients with mild-to-moderate symptomatic COVID-19. The trial met the primary endpoint, with a dose of 600mg of AZD7442 given by intramuscular […]
COVID-19 - October 8, 2021
New biomarker for severe COVID-19 found
Researchers at Karolinska Institutet have identified metabolic processes that SARS-CoV-2 uses to attack lung tissue. The results, which are published in Molecular & Cellular Proteomics, could be used to treat COVID-19, and potentially for other viruses like the Crimean-Congo hemorrhagic fever virus and HIV-1, states the researchers. The metabolic pathways that the virus “prefers” when […]
COVID-19 - October 5, 2021
AstraZeneca requests AZD7442 for emergency use authorization
AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic COVID-19. If granted, AZD7442 would be the first LAAB to receive an EUA for COVID-19 prevention. It is the first LAAB with Phase III data […]
COVID-19 - October 4, 2021
Merck’s molnupiravir reduced the risk of hospitalization or death by 50%
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics have announced that molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. “With these compelling results, we […]
COVID-19 - October 1, 2021
The pandemic: Consequences, side-effects and new insights
The Nordic life science industry has not only survived, but managed to grow and develop during the pandemic. The past 1.5 years have also brought valuable lessons, including the importance of collaboration and how to shorten development pathways in other areas too. Since February/March 2020, the pandemic has turned societies all around the world upside […]
